Arix Pegs LogicBio's Technology As 'Occam's Razor' Of Gene Therapy

Gene therapy startup LogicBio, with input from Arix Biosciences, has raised almost $50m via a series B financing round; it plans to use the cash to continue development of a potential novel alternative to traditional gene therapy.

DNA

LogicBio Therapeutics has raised $45m in a series B financing, led by Arix Biosciences, bringing to $50m the total the recently launched firm has raised to complete preclinical development of an innovative gene therapy platform for pediatric diseases and move lead programs into clinical studies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business